Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Stemline Therapeutics
Deal Size : $512.0 million
Deal Type : Licensing Agreement
Menarini Group Signs Exclusive License for KAT6 Inhibitor for Breast Cancer
Details : Stemline will have global rights to develop a novel KAT6A inhibitor designed using Insilico’s AI platform, targeting hormone-sensitive cancers and other oncology indications.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $12.0 million
April 01, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Stemline Therapeutics
Deal Size : $512.0 million
Deal Type : Licensing Agreement
Lead Product(s) : ISM3091
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Exelixis
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Insilico granted Exelixis an exclusive, worldwide license to develop and commercialize ISM3091, a best-in-class small molecule inhibitor of USP1, as a synthetic lethal target in the context of BRCA-mutated tumors, and other USP1-targ...
Product Name : ISM3091
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 09, 2023
Lead Product(s) : ISM3091
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Exelixis
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : ISM025
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Insilico's PCC molecule, ISM025 demonstrated potential when targeted against a broad range of tumor lineages with HRD backgrounds. In vitro data showed potent anti-proliferation activity of the compound in BRCA-mutant tumor cells with excellent selectivi...
Product Name : ISM025
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 13, 2022
Lead Product(s) : ISM025
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TCRT-ESO-A2
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : PharmaEssentia
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Axis Therapeutics and PharmaEssentia will collaborate to conduct an initial clinical study of Axis Therapeutics’ TCRT-ESO-A2 therapy, targeting solid tumors that are NY-ESO-1 positive in HLA-A positive patients, and to manufacture the investigational p...
Product Name : TCRT-ESO-A2
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
October 13, 2020
Lead Product(s) : TCRT-ESO-A2
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : PharmaEssentia
Deal Size : Undisclosed
Deal Type : Collaboration